Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000...
-
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
-
Juve Stabia President Andrea Langella (left) and Brera Holdings Executive Chairman Dan McClory (right) at the Club’s summer training camp in July 2024. DUBLIN, Ireland and MILAN, Italy, Dec. 09,...
-
Tel Aviv, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace,...
-
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the...
-
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney FunctionVIVA-MIND Phase 2 data confirm results of...
-
TOKYO, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family...
-
MELBOURNE, Australia, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. ("Fluence" or the “Company”) (NASDAQ: FLNC), a global market leader delivering intelligent energy storage, operational...
-
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated,...
-
Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L r/m PD-L1-exprimierendem HNSCC läuft, Aktualisierung der klinischen Daten für 2025 geplant Evaluierung von Petosemtamab bei mCRC auf 1L...